Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)

Cardiovasc Diabetol. 2025 Dec 5;24(1):454. doi: 10.1186/s12933-025-03014-x.ABSTRACTBACKGROUND: The mechanisms underlying cardiorenal benefits of finerenone remain unclear. This mechanistic trial aimed to evaluate the effects of finerenone on vascular stiffness, as assessed using the cardio-ankle vas

A Atsushi Tanaka

Assessing the impact of educational intervention based on a health belief model to modify cardiovascular disease risk factors among Egyptian University administrative staff: a quasi-experimental study

BMC Cardiovasc Disord. 2025 Dec 5. doi: 10.1186/s12872-025-05359-3. Online ahead of print.ABSTRACTBACKGROUND: Globally, cardiovascular diseases (CVDs) are acknowledged as a primary cause of death and morbidity. Using the health belief model (HBM) can help individuals believe in adopting a healthy li

A Abeer H Ahmed

The neuro-cardiac axis in epilepsy

Eur J Intern Med. 2025 Dec 4:106631. doi: 10.1016/j.ejim.2025.106631. Online ahead of print.ABSTRACTEpilepsy is a major noncommunicable neurological disorder, most prevalent among patients with cardiovascular (CV) disease (CVD). Epilepsy incurs a higher risk for developing CVD with an odds ratio of

T Theodora A Manolis